Fundz

Ellipses In-Licences 'GENA-104' for Developing Next-Generation Immuno-Oncology Drug

Feb 11, 2025

Contract Type

agreement

United Arab EmiratesBiotechnologyHealth CareMedicalTherapeuticsPharmaceutical

Description

Ellipses Pharma Limited has agreed to in-license global rights to 'GENA-104', a first-in-class immuno-oncology monoclonal antibody targeting CNTN4, a recently discovered checkpoint protein highly expressed in a wide range of tumor types. This agreement aims to accelerate the development of a novel immuno-oncology treatment strategy.

Company Information

Company

Ellipses Pharma Limited

Location

United Arab Emirates

About

Ellipses Pharma Limited is a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model. The company aims to find outstanding potential cancer treatments and develop them swiftly, supported by a strong investor base. Ellipses specializes in next generation selective RET inhibitors for treating RET-altered tumors, particularly in non-small cell lung and thyroid cancers. Its mission includes bringing hope and innovative therapies to patients, especially in the Middle East.

Related People

David
Likely contact at this company
••••••••@••••••••

See David's verified email →

Ascanio
Likely contact at this company
••••••••@••••••••

See Ascanio's verified email →

Luke
Likely contact at this company
••••••••@••••••••

See Luke's verified email →

Eden
Likely contact at this company
••••••••@••••••••

See Eden's verified email →

Suzanne
Likely contact at this company
••••••••@••••••••

See Suzanne's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Ellipses Pharma Limited's next move

Learn about Strategic plan

Ellipses Pharma Limited signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.